retatrutide triple hormone receptor agonist retatrutide Retatrutide: breakthrough… or still too early?, is an investigational triple-hormone (GLP-1 + GIP + glucagon) designed to go beyond current metabolic therapies by Today, we shared new data

Each individual's response to semaglutide can vary based on multiple factors, including their metabolic rate, lifestyle, and personal health history

November 7, 2022

It wasnt the medication

Dose can be increased in 2.5 mg increments every four weeks to a maximum of 15 mg weekly

Although retatrutide is not yet available outside of clinical trials, the factors that influence starting dose and titration speed are broadly consistent with those applied to similar licensed medicines

Research shows that maintaining healthy testosterone levels during weight loss supports cardiovascular function, while testosterone deficiency is associated with increased cardiovascular risk